Keywords: UK, NICE, GlaxoSmithKline, Arzerra, Eli Lilly, Alimta, Bristol-Myers Squibb, Orencia, Leukemia, NSCLC, Rheumatoid arthritis

UK’s NICE unable to recommend GlaxoSmithKline’s leukemia drug Arzerra, but backs Lilly’s Alimta for lung cancer; reverses decision on B-MS’ Orencia

Article | 25 June 2010

Print This

In preliminary draft guidance published yesterday by the UK’s National Institute for Health and Clinical Excellence (NICE), domestic drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in